Home LiteratureArticle Details
PMID: 15616284 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase.

Antimicrobial agents and chemotherapy ·Vol. 49 ·No. 1 ·2005-01-00 ·Pages 118-25

Tran JH, Jacoby GA, Hooper DC

Abstract

Quinolone resistance normally arises by mutations in the chromosomal genes for type II topoisomerases and by changes in the expression of proteins that control the accumulation of quinolones inside bacteria. A novel mechanism of plasmid-mediated quinolone resistance was recently reported that involves DNA gyrase protection by a pentapeptide repeat family member called Qnr. This family includes two other members, McbG and MfpA, that are also involved in resistance to gyrase inhibitors. Purified Qnr-His(6) was shown to protect Escherichia coli DNA gyrase directly from inhibition by ciprofloxacin. Here we have provided a biochemical basis for the mechanism of quinolone resistance. We have shown that Qnr can bind to the gyrase holoenzyme and its respective subunits, GyrA and GyrB. The binding of Qnr to gyrase does not require the presence of the complex of enzyme, DNA, and quinolone, since binding occurred in the absence of relaxed DNA, ciprofloxacin, or ATP. We hypothesize that the formation of Qnr-gyrase complex occurs before the formation of the cleavage complex. Furthermore, there was a decrease in DNA binding by gyrase when the enzyme interacted with Qnr. Therefore, it is possible that the reaction intermediate recognized by Qnr is one early in the gyrase catalytic cycle, in which gyrase has just begun to interact with DNA. Quinolones bind later in the catalytic cycle and stabilize a ternary complex consisting of the drug, gyrase, and DNA. By lowering gyrase binding to DNA, Qnr may reduce the amount of holoenzyme-DNA targets for quinolone inhibition.

MeSH Terms
Anti-Bacterial Agents/pharmacology Anti-Infective Agents/pharmacology Ciprofloxacin/pharmacology DNA Gyrase/metabolism Drug Resistance, Bacterial/genetics Escherichia coli/drug effects,genetics,metabolism Escherichia coli Proteins/metabolism Plasmids/genetics Quinolones/pharmacology Recombinant Fusion Proteins/metabolism
Chemicals
Anti-Bacterial Agents Anti-Infective Agents Escherichia coli Proteins Qnr protein, E coli Quinolones Recombinant Fusion Proteins Ciprofloxacin DNA Gyrase
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Tran John H
Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114-2696, USA.
Jacoby George A
Hooper David C
References (40)
40 references, click to expand
  1. Quinolone resistance due to reduced target enzyme expression.
    J Bacteriol. 2003 Dec;185(23):6883-92 PMID: 14617652
  2. A model for the mechanism of strand passage by DNA gyrase.
    Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8414-9 PMID: 10411889
  3. DNA sequencing with chain-terminating inhibitors.
    Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 PMID: 271968
  4. Site-specific cleavage of DNA by E. coli DNA gyrase.
    Cell. 1979 May;17(1):175-84 PMID: 378403
  5. Repair of near-ultraviolet (365 nm)-induced strand breaks in Escherichia coli DNA. The role of the polA and recA gene products.
    Biophys J. 1986 Feb;49(2):485-91 PMID: 3513859
  6. The export of the DNA replication inhibitor Microcin B17 provides immunity for the host cell.
    EMBO J. 1988 Jun;7(6):1853-62 PMID: 3049078
  7. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.
    Antimicrob Agents Chemother. 1990 Jun;34(6):1271-2 PMID: 2168148
  8. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.
    Antimicrob Agents Chemother. 1991 Aug;35(8):1647-50 PMID: 1656869
  9. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
    Cancer Res. 1992 Aug 15;52(16):4467-72 PMID: 1322791
  10. The interaction of DNA gyrase with the bacterial toxin CcdB: evidence for the existence of two gyrase-CcdB complexes.
    J Mol Biol. 1999 Oct 29;293(3):733-44 PMID: 10543963
  11. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.
    Antimicrob Agents Chemother. 2000 Sep;44(9):2233-41 PMID: 10952561
  12. DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex.
    J Biol Chem. 2000 Nov 3;275(44):34780-6 PMID: 11053451
  13. The complex of DNA gyrase and quinolone drugs on DNA forms a barrier to the T7 DNA polymerase replication complex.
    J Mol Biol. 2000 Dec 15;304(5):779-91 PMID: 11124026
  14. The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition.
    J Mol Biol. 2001 Apr 13;307(5):1223-34 PMID: 11292337
  15. Emerging mechanisms of fluoroquinolone resistance.
    Emerg Infect Dis. 2001 Mar-Apr;7(2):337-41 PMID: 11294736
  16. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).
    Antimicrob Agents Chemother. 2001 Jul;45(7):1994-2000 PMID: 11408214
  17. Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA.
    Antimicrob Agents Chemother. 2001 Dec;45(12):3387-92 PMID: 11709313
  18. DNA topoisomerases: structure, function, and mechanism.
    Annu Rev Biochem. 2001;70:369-413 PMID: 11395412
  19. GyrI: a counter-defensive strategy against proteinaceous inhibitors of DNA gyrase.
    EMBO Rep. 2002 Mar;3(3):261-7 PMID: 11850398
  20. Characterization of the interaction between DNA gyrase inhibitor and DNA gyrase of Escherichia coli.
    J Biol Chem. 2002 Mar 15;277(11):8949-54 PMID: 11777918
  21. Crystal structure of the Escherichia coli SbmC protein that protects cells from the DNA replication inhibitor microcin B17.
    Proteins. 2002 May 15;47(3):403-7 PMID: 11948793
  22. Mechanism of plasmid-mediated quinolone resistance.
    Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5638-42 PMID: 11943863
  23. ParE toxin encoded by the broad-host-range plasmid RK2 is an inhibitor of Escherichia coli gyrase.
    Mol Microbiol. 2002 May;44(4):971-9 PMID: 12010492
  24. Interaction of plasmid and host quinolone resistance.
    J Antimicrob Chemother. 2003 Apr;51(4):1037-9 PMID: 12654766
  25. Chromosomally encoded gyrase inhibitor GyrI protects Escherichia coli against DNA-damaging agents.
    Arch Microbiol. 2003 Nov;180(5):339-46 PMID: 13680098
  26. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.
    Biochemistry. 1989 May 2;28(9):3886-94 PMID: 2546585
  27. Tryptic fragments of the Escherichia coli DNA gyrase A protein.
    J Biol Chem. 1989 Nov 25;264(33):19648-53 PMID: 2555327
  28. Plasmid-mediated 4-quinolone resistance: a real or apparent absence?
    Antimicrob Agents Chemother. 1990 May;34(5):681-4 PMID: 2193615
  29. The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases.
    Cell. 1992 Nov 27;71(5):833-40 PMID: 1330327
  30. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
    Cancer Res. 1994 Apr 1;54(7):1795-800 PMID: 8137294
  31. Antitopoisomerase drug action and resistance.
    Eur J Cancer. 1996 Jun;32A(6):958-66 PMID: 8763336
  32. Conversion of DNA gyrase into a conventional type II topoisomerase.
    Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14416-21 PMID: 8962066
  33. DNA gyrase, topoisomerase IV, and the 4-quinolones.
    Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92 PMID: 9293187
  34. Identification of DNA gyrase inhibitor (GyrI) in Escherichia coli.
    J Biol Chem. 1998 Jan 23;273(4):1933-8 PMID: 9442027
  35. Quinolone resistance from a transferable plasmid.
    Lancet. 1998 Mar 14;351(9105):797-9 PMID: 9519952
  36. Identification of active site residues in the "GyrA" half of yeast DNA topoisomerase II.
    J Biol Chem. 1998 Aug 7;273(32):20252-60 PMID: 9685374
  37. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities.
    Biochim Biophys Acta. 1998 Oct 1;1400(1-3):29-43 PMID: 9748489
  38. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine.
    Q Rev Biophys. 1998 May;31(2):107-44 PMID: 9794033
  39. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands.
    Nat Struct Biol. 1999 Apr;6(4):322-6 PMID: 10201398
  40. DNA gyrase: an enzyme that introduces superhelical turns into DNA.
    Proc Natl Acad Sci U S A. 1976 Nov;73(11):3872-6 PMID: 186775
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
2005-01-00
Pages
118-25
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC538914
Subset
IM
Grants
NIAID NIH HHS · R01 AI043312 · United States
NIAID NIH HHS · R01 AI057576 · United States
NIAID NIH HHS · AI43312 · United States
NIAID NIH HHS · AI57576 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com